bevacizumab: Definition, Uses, and Clinical Overview

bevacizumab Introduction (What it is)

bevacizumab is a medication that blocks a signal involved in abnormal blood vessel growth.
It is a monoclonal antibody (a targeted protein drug) originally developed for certain cancers.
In eye care, it is commonly used as an intravitreal injection, meaning it is placed into the vitreous gel inside the eye.
Ophthalmologists most often use it to treat retinal conditions that cause swelling or bleeding and can threaten vision.

Why bevacizumab used (Purpose / benefits)

Many vision-threatening retinal diseases share a similar pathway: the eye produces higher levels of vascular endothelial growth factor (VEGF). VEGF is a natural protein that helps the body form new blood vessels, but in the retina it can drive fragile, leaky abnormal vessels and fluid leakage.

bevacizumab is used to reduce the effects of VEGF in the eye. In general terms, the goals are to:

• Reduce retinal swelling (macular edema): Fluid can collect in or under the macula (the central retina responsible for detailed vision), causing blur and distortion.
• Limit abnormal blood vessel growth (neovascularization): New vessels can bleed or form scar tissue, potentially leading to more serious retinal damage.
• Stabilize or improve vision in responsive conditions: Outcomes vary by diagnosis, severity, and how early treatment begins.
• Support other treatments: It may be used alongside laser procedures or surgery, depending on the case.

Because many retinal diseases are chronic, the “benefit” of bevacizumab is often thought of as disease control over time—keeping fluid, bleeding, and activity suppressed—rather than a one-time cure.

Indications (When ophthalmologists or optometrists use it)

Common eye-related scenarios where bevacizumab may be used include:

• Neovascular (wet) age-related macular degeneration (AMD)
• Diabetic macular edema (DME)
• Proliferative diabetic retinopathy (PDR), including neovascularization of the retina or optic disc
• Macular edema from retinal vein occlusion (branch or central retinal vein occlusion)
• Choroidal neovascularization (CNV) from causes other than AMD (example: high myopia), when clinically appropriate
• Adjunctive use before or after certain retinal surgeries (varies by clinician and case)
• Selected cases of neovascular glaucoma management as part of a broader plan (varies by clinician and case)
• Other off-label retinal vascular or inflammatory scenarios where VEGF is a major driver (varies by clinician and case)

Contraindications / when it’s NOT ideal

Whether bevacizumab is suitable depends on the eye condition, overall health, and treatment goals. Situations where it may be avoided or another approach may be preferred include:

• Active eye infection (for example, conjunctivitis, keratitis, or suspected endophthalmitis) when an intravitreal injection could worsen infection risk
• Significant active inflammation inside the eye (uveitis) in which the timing or choice of medication may differ
• Known allergy or hypersensitivity to bevacizumab or components used in preparation (rare but relevant)
• Situations where a different anti-VEGF agent is preferred due to clinician experience, regulatory status, dosing strategy, or patient-specific response (varies by clinician and case)
• Pregnancy or breastfeeding considerations: anti-VEGF therapy is often approached cautiously because VEGF has roles in normal blood vessel development; decisions vary by clinician and case
• Recent major cardiovascular events (such as stroke or heart attack): systemic anti-VEGF exposure is much higher with cancer dosing than with eye dosing, but clinicians may still weigh risks and benefits on an individual basis
• When non-injection options are more appropriate: for some patterns of disease, laser treatment, surgery, or observation may be considered instead (varies by clinician and case)

How it works (Mechanism / physiology)

Mechanism of action: bevacizumab binds to VEGF-A, reducing VEGF’s ability to activate receptors on blood vessel cells. In retinal disease, this can decrease:

• Leakage from existing vessels (helping reduce macular edema)
• Growth of abnormal new vessels (reducing neovascularization)

Relevant eye anatomy:
Most ophthalmic uses focus on the retina, especially the macula (central retina) and the choroid (the vascular layer beneath the retina). In conditions like wet AMD and some forms of CNV, abnormal vessels develop under or within the retina and can leak fluid or bleed. In diabetes and vein occlusions, retinal blood vessels become damaged and leaky, leading to swelling and sometimes ischemia (poor oxygen), which can increase VEGF levels.

Onset, duration, reversibility:
After an intravitreal injection, anti-VEGF effects can begin relatively soon, but the clinical timing of improvement varies (for example, fluid on imaging may reduce before vision changes are noticed). The medication effect is not permanent; VEGF activity can return as the drug level decreases. For many conditions, ongoing monitoring and repeat treatment may be needed, with the schedule individualized to disease activity.

bevacizumab Procedure overview (How it’s applied)

bevacizumab is a medication, not a procedure, but in ophthalmology it is most often delivered through an intravitreal injection performed in a clinical setting.

A typical workflow, at a high level, includes:

1. Evaluation / exam
   – Symptom review and vision testing
   – Dilated retinal exam
   – Imaging such as optical coherence tomography (OCT) to assess macular fluid
   – Sometimes additional tests (for example, fluorescein angiography) depending on the diagnosis

2. Preparation
   – Discussion of goals, expected course, and potential risks
   – Medication verification and handling (often prepared in small doses for eye use; source and preparation standards vary by setting)
   – Antiseptic cleaning of the ocular surface and eyelids
   – Numbing drops or local anesthetic to reduce discomfort

3. Intervention
   – Intravitreal placement of the medication using a fine needle under sterile technique
   – The injection itself is typically brief

4. Immediate checks
   – Quick assessment of comfort and vision symptoms
   – Clinician may check eye pressure or confirm adequate retinal circulation, depending on practice patterns

5. Follow-up
   – Monitoring response with repeat exams and OCT imaging
   – Future injection timing is based on disease activity and treatment plan (varies by clinician and case)

Types / variations

In eye care, “types” of bevacizumab use usually refers to how it is used rather than different formulations designed specifically for the eye.

Common variations include:

• Route of administration
• Intravitreal bevacizumab: the most common ophthalmic route

• Other routes (less common in routine care): topical or subconjunctival use has been described for certain surface or anterior-segment neovascular issues, but practices vary and are more case-dependent

• On-label vs off-label use

• bevacizumab is widely known for off-label ophthalmic use in several retinal diseases. “Off-label” means the medication is used in a way not specifically listed in the regulatory approval, based on clinical judgment and available evidence.

• Treatment strategies

• Loading phase then maintenance: some plans start with more frequent injections and later adjust
• Treat-and-extend: intervals are gradually lengthened if the retina remains stable

• PRN (as needed): injections are given when signs of disease activity return
  These strategies are chosen based on diagnosis, response, and clinician preference.

• Product and preparation considerations

• bevacizumab for eye injections is often supplied in a larger vial and then divided into smaller doses for ophthalmic use. Handling and preparation methods vary by facility and local standards.

Pros and cons

Pros:

• Can reduce macular fluid and retinal leakage in VEGF-driven conditions
• Often helps control abnormal vessel growth that can bleed or scar
• Typically performed as an outpatient office-based treatment
• Can be repeated and adjusted over time based on disease activity
• May be used as part of combination care (with laser or surgery when appropriate)
• Broad clinical experience in retinal practice for multiple indications

Cons:

• Requires injections into the eye, which some patients find stressful
• Effect is time-limited; repeat treatments and monitoring are often needed
• Potential risks associated with intravitreal injections (infection, bleeding, inflammation, pressure changes), even when uncommon
• Not everyone responds equally; some eyes need a different medication approach (varies by clinician and case)
• Logistical burden: frequent visits, imaging, and follow-ups can be challenging
• Off-label status in many eye indications can affect consent discussions, policies, and coverage (varies by health system and insurer)

Aftercare & longevity

After an intravitreal injection, clinicians typically provide guidance on what to expect in the short term and when to report symptoms. While experiences vary, people may notice temporary irritation, mild redness, or a sensation of grittiness from the antiseptic or the procedure.

Longevity of results depends on the underlying condition and its activity:

• Disease type and severity: wet AMD, DME, and vein occlusions can behave differently over time.
• Baseline retinal damage: longstanding swelling or scarring may limit visual improvement even if fluid decreases.
• Treatment schedule and follow-up consistency: anti-VEGF therapy commonly requires ongoing reassessment with OCT and exams.
• Other eye health factors: cataract status, glaucoma, and ocular surface comfort can affect perceived vision and tolerance of visits.
• Systemic health and risk factors: diabetes control and blood pressure management can influence retinal disease course, though individual outcomes vary.

In many retinal diseases, the practical goal is long-term control—keeping the macula as dry as possible and preventing new bleeding or scarring—while balancing visit frequency and patient needs.

Alternatives / comparisons

Alternatives to bevacizumab depend on the diagnosis and the pattern of disease activity. Common comparisons include:

• Other anti-VEGF medications
  Options such as ranibizumab, aflibercept, brolucizumab, and faricimab may be used for similar retinal indications. Differences may include regulatory labeling, dosing intervals used in practice, clinician experience, and individual response. No single agent is ideal for every patient; selection varies by clinician and case.

• Steroid-based treatments (for selected macular edema cases)
  Intravitreal steroids (for example, triamcinolone or steroid implants) may be considered in certain types of macular edema, particularly when inflammation is a major component or when anti-VEGF response is limited. Steroids have their own trade-offs, including the potential to raise eye pressure or accelerate cataract formation.

• Laser treatments

• Focal/grid laser may be used in selected macular edema patterns (more commonly historically, and still used in some scenarios).

• Panretinal photocoagulation (PRP) is a key treatment for proliferative diabetic retinopathy to reduce the drive for neovascularization. Anti-VEGF injections and PRP are sometimes used together, depending on the case.

• Surgery (vitrectomy) or procedural management
  When there is non-clearing vitreous hemorrhage, traction, or retinal detachment risk, surgery may be part of care. Anti-VEGF can be used as an adjunct in some surgical planning, but surgical decisions are individualized.

• Observation / monitoring
  Some retinal findings can be monitored before initiating injections, especially if fluid is minimal, vision is stable, or the diagnosis is uncertain. Monitoring typically involves repeat exams and imaging.

bevacizumab Common questions (FAQ)

Q: Is bevacizumab an eye medicine or a cancer medicine?
bevacizumab was originally developed for systemic use in certain cancers. In ophthalmology, it is commonly used as an intravitreal injection to treat retinal diseases driven by VEGF. Using it in the eye is often considered “off-label,” meaning it is not specifically listed in some regulatory approvals for that indication.

Q: Does the injection hurt?
Most people report pressure or brief discomfort rather than sharp pain because numbing medication is typically used. Sensations vary due to individual sensitivity and technique differences. Temporary irritation afterward can occur.

Q: How long do bevacizumab results last?
The medication effect is not permanent, and retinal diseases often require ongoing monitoring. Some eyes need repeat injections on a regular schedule, while others can extend intervals once stable. The timeline varies by clinician and case and by how active the disease is.

Q: Is bevacizumab considered safe for the eye?
Intravitreal anti-VEGF injections are commonly performed in retinal care, and many clinicians have extensive experience with them. However, any injection into the eye carries risks, including infection (endophthalmitis), inflammation, bleeding, or eye pressure changes. Safety discussions are individualized and part of informed consent.

Q: Why might a clinician choose bevacizumab instead of another anti-VEGF drug?
Choice can depend on availability, clinician experience, healthcare system policies, and how an individual eye responds. Cost and coverage considerations may also influence selection, since pricing and reimbursement can vary. The “best” option is not the same for every person or condition.

Q: Can I drive myself home after an injection?
Some people can, but others prefer not to because dilation, temporary blur, light sensitivity, or irritation may affect comfort and vision shortly after the visit. Clinic routines differ, and individual responses vary. Many patients arrange transportation for convenience, especially for first-time injections.

Q: Will bevacizumab cure wet AMD or diabetic eye disease?
These conditions are typically chronic and related to ongoing biological signals such as VEGF and vascular damage. bevacizumab is generally used to control disease activity—reducing leakage and abnormal vessel growth—rather than providing a permanent cure. Long-term outcomes depend on baseline damage, consistency of monitoring, and disease behavior.

Q: What follow-up testing is usually done?
OCT imaging is commonly used to track retinal swelling and fluid response over time. Clinicians also monitor vision, examine the retina, and may use additional imaging when needed. The follow-up schedule is tailored to the diagnosis and treatment plan.

Q: How much does bevacizumab cost?
Costs vary widely by country, clinic setting, insurance coverage, and how the medication is supplied and prepared. There may be separate charges for the drug, the injection procedure, and imaging tests. Your clinic or insurer can explain typical out-of-pocket expectations in your situation.